2. Joham A.E., Norman R.J., Stener-Victorin E., et al. Polycystic ovary syndrome. Lancet. Diab Endocrinol. 2022;10:668–80. doi: 10.1016/S2213-8587(22)00163-2.

3. Tomlinson J.A., Pinkney J.H., Evans P., et al. Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome. Br J Diab Vasc Dis. 2013;13(3):115–23.

4. Teede H.J., Misso M.L., Michael F., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome Fertil Steril. 2018;10(3):364–269. doi: 10.1016/j.fertnstert.2018.05.004.

5. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Hum Reprod. 2004;19:41–7. doi: 10.1093/humrep/deh098.

6. De Leo V., Musacchio M.C., Cappelli V., et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14(1):38. doi: 10.1186/s12958-016-0173-x.

7. Wawrzkiewicz-Jałowiecka A., Kowalczyk K., Trybek P., et al. In Search of New Therapeutics-Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. Int J Mol Sci. 2020;21(19):7054. doi: 10.3390/ijms21197054.

8. Silva M.S.B., Giacobini P. New insights into anti-Mullerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development. Cell Mol Life Sci. 2021;78(1):1–16. doi: 10.1007/s00018-020-03576-x.

9. Azziz R., Carmina E., Dewailly D., et al., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88. doi: 10.1016/j.fertnstert.2008.06.035.

10. Quinn M., Shinkai K., Pasch L., et al. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril. 2014;101:1129–34. doi: 10.1016/j.fertnstert.2014.01.003.

11. Ramezani Tehrani F., Behboudi-Gandevani S., Bidhendi Yarandi R., et al. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis. Gynecol Endocrinol. 2021;37:392–405. doi: 10.1080/09513590.2020.1859474.

12. Franks S., Hardy K. Androgen Action in the Ovary. Front Endocrinol. (Lausanne). 2018;9:452. doi: 10.3389/fendo.2018.00452.

13. O’Reilly M.W., Taylor A.E., Crabtree N.J., et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab. 2014;99:1027–36. doi: 10.1210/jc.2013-3399.

14. Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women. Med Arch. 2020;74:289–93. Doi: 10.5455/medarh.2020.74.289-293.

15. Lie Fong S., Laven J.S.E., Duhamel A., Dewailly D. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Mullerian hormone using cluster analysis. Hum Reprod. 2017;32(8):1723–31. Doi: 10.1093/humrep/dex226.

16. Shilpa K., Earlina A., Larysa S. The Clinical Manifestations of Polycystic Ovary Syndrome (PCOS) and The Treatment Options. Eur J Biol Med Sci. Res. 2023;11:57–91.

17. Kumarapeli V., Seneviratne Rde A., Wijeyaratne C.N.,et al. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol. 2008;168(3):321–28. Doi: 10.1093/aje/kwn137.

18. Joham A.E., Teede H.J., Ranasinha S., et al. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. J Womens Health (Larchmt). 2015;24(4):299–307. Doi: 10.1089/jwh.2014.5000.

19. Nisenblat V., Norman R.J. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diab Obes. 2009;16:224–31. Doi: 10.1097/MED.0b013e32832afd4d.

20. Norman R.J., Morman R., Teede H.J. «Tis but thy name that is my enemy»-the problem with the naming of polycystic ovary syndrome. Fertil Steril. 2023 Mar 27;S0015-0282(23)00237-6. Doi: 10.1016/j.fertnstert.2023.03.028.

21. Christ J.P., Cedars M.I. Current Guidelines for Diagnosing PCOS. Diagnost (Basel). 2023;13(6):1113. Doi: 10.3390/diagnostics13061113.

22. Tosi F., Bonora E., Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: A comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32:2515–21. Doi: 10.1093/humrep/dex308.

23. Cassar S., Misso M.L., Hopkins W.G., et al. Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31:2619–31. Doi: 10.1093/humrep/dew243.

24. Lim S.S., Davies M.J., Norman R.J., Moran L.J. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618–37. Doi: 10.1093/humupd/dms030.

25. Ovalle F., Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77(6):1095–105. Doi: 10.1016/s0015-0282(02)03111-4.

26. Unluhizarci K., Karaca Z., Kelestimur F. Role of insulin and insulin resistance in androgen excess disorders. World J Diab. 2021;12:616–29. Doi: 10.4239/wjd.v12.i5.616.

27. Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95:2515–6. Doi: 10.1016/j.fertnstert.2011.05.027.

28. Wallace I.R., McKinley M.C., Bell P.M., Hunter S.J. Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf). 2013;78:321–29. doi: 10.1111/cen.12086.

29. Unfer V., Carlomagno G., Papaleo E., et al. Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014;21:854–8. Doi: 10.1177/1933719113518985.

30. Heimark D., McAllister J., Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61:111–17. Doi: 10.1507/endocrj.ej13-0423.

31. Facchinetti F., Dante G., Neri I. The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences. Front Gynecol Endocrinol. 2016;3:103–9.

32. Lagana A.S., Garzon S., Casarin J., et al. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab. 2018;29:768–80. Doi: 10.1016/j.tem.2018.09.001.

33. Monastra G., Vazquez-Levin M., Bezerra Espinola M.S., et al. D-chiro-inositol, an aromatase down-modulator, increases androgens and reduces estrogens in male volunteers: a pilot study. Basic Clin Androl. 2021;31:13.

34. Bremer A.A., Miller W.L. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril. 2008;89(5):1039–48. Doi: 10.1016/j.fertnstert.2008.02.091.

35. Diamanti-Kandarakis E., Papalou O., Kandaraki E.A. The Role of Androgen Excess on Insulin Sensitivity in Women. Front Horm Res. 2019;53:50–64. Doi: 10.1159/000494902.

36. Tuorila K., Ollila M.M., Jarvenlin M.R., et al. Hyperandrogenemia in early adulthood is an independent risk factor for abnormal glucose metabolism in middle age. J Clin Endocrinol Metab. 2021;106(11):e4621–33. Doi: 10.1210/clinem/dgab456.

37. Alviggi C., Conforti A., De Rosa P., et al. The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome. Front Endocrinol. (Lausanne). 2017;8:117. Doi: 10.3389/fendo.2017.00117.

38. Moghetti P., Tosi F., Bonin C., et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E628–37. Doi: 10.1210/jc.2012-3908.

39. Dai S., Zhang H., Yang F., et al. Effects of IGF-1 on the Three-Dimensional Culture of Ovarian Preantral Follicles and Superovulation Rates in Mice. Biology (Basel). 2022;11(6):833. Doi: 10.3390/biology11060833.

40. Young C.H., Snow B., DeVore S.B., et al. Progesterone stimulates histone citrullination to increase IGFBP1 expression in uterine cells. Reproduct. 2021;162:117–27. Doi: 10.1530/REP-21-0132.

41. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27–36. Doi: 10.1016/j.jsbmb.2018.04.008.

42. Unfer V., Dinicola S., Russo M. A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes? Int J Mol Sci. 2023;24. doi: 10.3390/ijms24076213.

43. Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: Comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23:5512–21. doi: 10.26355/eurrev_201906_18223.

44. Thalamati S. A comparative study of combination of Myo-inositol and D-chiro-inositol versus Metformin in the management of polycystic ovary syndrome in obese women with infertility. Int J Reprod Contracept Obstet Gynecol. 2019;8:825–29.

45. Bevilacqua A., Dragotto J., Giuliani A., Bizzarri M. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019;234:9387–98. Doi: 10.1002/jcp.27623.

46. Bevilacqua A., Dragotto J., Lucarelli M., et al. High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. Int J Mol Sci. 2021;22:5691. Doi: 10.3390/ijms22115691.